These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 7536381)

  • 1. Cicaprost inhibits collagen-induced platelet accumulation in rat lungs for some hours.
    Nowak G; Bucha E
    Agents Actions Suppl; 1995; 45():101-6. PubMed ID: 7536381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers.
    Belch JJ; McLaren M; Lau CS; Mackay IR; Bancroft A; McEwen J; Thompson JM
    Br J Clin Pharmacol; 1993 Jun; 35(6):643-7. PubMed ID: 8329292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral cicaprost reduces platelet and neutrophil activation in experimental hypercholesterolemia.
    Hohlfeld T; Weber A; Schrör K
    Agents Actions Suppl; 1992; 37():289-96. PubMed ID: 1632303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Functional and ligand binding studies suggest heterogeneity of platelet prostacyclin receptors.
    Armstrong RA; Lawrence RA; Jones RL; Wilson NH; Collier A
    Br J Pharmacol; 1989 Jul; 97(3):657-68. PubMed ID: 2474350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral naftidrofuryl prevents platelet hyperreactivity ex vivo and inhibits functional desensitization to prostacyclin in hypercholesterolemic rabbits.
    Weber AA; Hohlfeld T; Strobach H; Schrör K
    J Cardiovasc Pharmacol; 1993 Feb; 21(2):332-8. PubMed ID: 7679170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-platelet and anti-thrombotic effects of OP-41483.alpha-CD, a prostacyclin analogue, in experimental animals.
    Katsube N; Sakaguchi K; Fujitani B; Aishita H
    Prostaglandins Leukot Essent Fatty Acids; 1993 Oct; 49(4):795-804. PubMed ID: 8259376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Iloprost, Cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets.
    Ashby B
    Prostaglandins; 1992 Mar; 43(3):255-61. PubMed ID: 1378640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergic effect of cicaprost-clathrate and low-dose acetylsalicylic acid on platelet aggregation in man.
    Mahler M; Seifert W; Spiegel B; Staks T
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):446-7. PubMed ID: 1490775
    [No Abstract]   [Full Text] [Related]  

  • 9. Enhanced platelet sensitivity to prostacyclin in patients in an active stage of Takayasu arteritis.
    Watanabe T; Kishi Y; Numano F; Isobe M
    Thromb Res; 2001 Oct; 104(2):77-83. PubMed ID: 11672751
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of ZK 36374, a stable prostacyclin analogue, on adhesion of rabbit platelets to damaged aorta and serotonin release by adherent platelets.
    Menys VC; Davies JA
    Clin Sci (Lond); 1983 Aug; 65(2):149-53. PubMed ID: 6190604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Control of human and animal platelet aggregation by a new prostacyclin analog.
    Maderna P; Colli S; Sirtori C; Tremoli E; Paoletti R
    Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():363-9. PubMed ID: 2408447
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic effects of KP-10614, a novel and stable prostacyclin (PGI2) analog.
    Kanayama T; Kimura Y; Iseki K; Hayashi Y; Tamao Y; Mizogami S
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1210-7. PubMed ID: 1702154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PGI2-analogue iloprost and the TXA2-receptor antagonist sulotroban synergistically inhibit TXA2-dependent platelet activation.
    Stürzebecher S; Witt W
    Prostaglandins; 1988 Dec; 36(6):751-60. PubMed ID: 2469101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of anti-aggregatory effects of PGI2, PGI3 and iloprost on human and rabbit platelets.
    Kobzar G; Mardla V; Järving I; Samel N
    Cell Physiol Biochem; 2001; 11(5):279-84. PubMed ID: 11684817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iloprost in peripheral vascular disease--platelet function and clinical outcome.
    Fitscha P; Tiso B; Sinzinger H
    Prog Clin Biol Res; 1987; 242():463-8. PubMed ID: 2444993
    [No Abstract]   [Full Text] [Related]  

  • 16. Interaction of antiplatelet drugs in vitro: aspirin, iloprost, and the nitric oxide donors SIN-1 and sodium nitroprusside.
    Negrescu EV; Grünberg B; Kratzer MA; Lorenz R; Siess W
    Cardiovasc Drugs Ther; 1995 Aug; 9(4):619-29. PubMed ID: 8547213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The novel effect of a new prostacyclin analogue ZK36374 on the aggregation of human platelets in whole blood.
    Saniabadi AR; Lowe GD; Belch JJ; Forbes CD; Prentice CR; Barbenel JC
    Thromb Haemost; 1983 Oct; 50(3):718-21. PubMed ID: 6196854
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterologous desensitization of platelet adenosine (A2) responses by iloprost.
    MacDermot J; Wilkins AJ; Edwards RJ
    Adv Prostaglandin Thromboxane Leukot Res; 1987; 17A():479-81. PubMed ID: 2444081
    [No Abstract]   [Full Text] [Related]  

  • 19. Octimibate, a potent non-prostanoid inhibitor of platelet aggregation, acts via the prostacyclin receptor.
    Merritt JE; Hallam TJ; Brown AM; Boyfield I; Cooper DG; Hickey DM; Jaxa-Chamiec AA; Kaumann AJ; Keen M; Kelly E
    Br J Pharmacol; 1991 Jan; 102(1):251-9. PubMed ID: 1710526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo studies with the stabilized epoprostenol analogue taprostene. Effects on platelet functions and blood clotting.
    Michel G; Seipp U
    Arzneimittelforschung; 1990 Aug; 40(8):932-8. PubMed ID: 2242087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.